pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-16-2 |
Genomic Coordinates | chr3: 160404745 - 160404825 |
Description | Homo sapiens miR-16-2 stem-loop |
Comment | This entry represents a second putative hairpin precursor sequence for miR-16, located on chromosome 3 (see also MIR:MI0000070). The sequence was previously named mir-16-3 here and in references . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-16-2-3p | ||||||||||||||||||
Sequence | 53| CCAAUAUUACUGUGCUGCUUUA |74 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SH3BP5 | ||||||||||||||||||||
Synonyms | SAB, SH3BP-5 | ||||||||||||||||||||
Description | SH3 domain binding protein 5 | ||||||||||||||||||||
Transcript | NM_001018009 | ||||||||||||||||||||
Other Transcripts | NM_004844 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SH3BP5 | |||||||||||||||||||||
3'UTR of SH3BP5 (miRNA target sites are highlighted) |
>SH3BP5|NM_001018009|3'UTR 1 TTCATCCTGGGCCCTGGCCGATGTGCATATCAACATTTATACATGGAACTGGAGAACATTGTGCCAATAATCATTTAATA 81 TATGCCAAATCTTACACGTCTACTCTAAACTGCTCTAATGAAGTTTCAGTGACCTTGAGGGCTAAAGATTGTTCTTCTGG 161 GTAAGAGCTCTTGGGCTGGTTTTTCAGAGCAGAGTTCTTGTTGTGGGTAGACTGTGACTAGGTTCACAGCCTTTGTGGAA 241 CATTCCGTATAACGGCATTGTGGAAGCAATAACTAGTTCCTATGAAAGAACCAGAGCTGGGAAGATGGCTGGGAAGCCAG 321 GCCAAAGTGGGGGCAACAGCTTGCTTCTCTTTCTCTTCTCACCCTCAGTTTGTATGGGAAAATGGAGATGTCCTCTCCAC 401 TTTATCCCACGATATCTAAATGAAAAAGAAAGAAAACCCACACACAAAGCAAAAACTCAAGTATTAAGAGCACATATTTT 481 TGACCCAGTGGAGGCTTAAAAAAAAAAAAATCCAAGAACACAATTCATTTTCACCACCTCTGGTGTTCAGAGGGGGCTTT 561 TAAAAAAGCGTGTATGCTGGGATACCCATTAAAACCATTTTCTAGAAGGCTACCATGAGCTGCACTTTTTGGGGTGGGAA 641 AGGTGAATGCCAGTGGGGATGCGGGGGGATGAGGGTAGGAGGGACTTATAGAAGGGGATTTGTGGCTGTGGGGGAGAAGG 721 TTCTACAGCATAAGCCTTATCCTGCCAGCCAAGGGGATTTATTCTAAGAGAAGTGCATGTGAAGAATGGTTGCCACTGTT 801 ATTAGATTGACAAGATGTTAATTTCTCTGTAGGTTGTAACTTTAAAAATAAATGAAATTATTTAAGGGTTATGCTGCACT 881 AGTATTCCTTAGAGGAAACAGTTCTTTAAAGTTAGGAAAGGGAGTAGGCAGGCATGTGTTGGCAAAGGCTGTTAATAGTA 961 GTTAAGTGTTAAGACTGCTTTTCTTTAACGTTTTCATGGTAATGCATATTTAGAGCACTGTATTTTTGTCTTGTTAAGAA 1041 AATTTAGCATTTCTAAAAGAAAAAAGCAACCCTCTTTCAAACTGTTAATTCTGTCACAGCCTGTATATTTTAGTCATTTG 1121 TAAATCTCTTCATACAATAGTGACTTCTTTTTTGACTGATACAGTATCTTAATTACAAGGTTATTTTGTACTTGTCTTAA 1201 TACACTAAGTGTAATAAAAACGGCTTGAGAAAAGTTTCTCCTTTCTGTGACTTCAAATAAGAACTCCCAGTATTGCCTAA 1281 ATCTTCTAGGCAACCCTTTTTCCATAAGGAAGAGCATGGAGTGCTGTGGTCACCAGTAATCATTTTCAATTAATTAAGGT 1361 CATGAACAGTAATAATTTAAGCCTTGTTTACCAAGGTTTGAATTCTACTTTTGCTGTTGCTAAAGCTGTGGGCAATGAGG 1441 AGACACAGTGGCAGATAAAGACGAGGTGGTGACGCTGGAGGAGTGGGCCTCGGCTGCACACTGCAGTCTCGAAGCTTAAG 1521 TGTTGCTGTCAGTCAGTTCTCATCCCCAGAGAATTATTTAATTAATTAACTGGGGGGGGTACACTGGGGCATTAGACTTT 1601 TAAAAGCTCCCCGAGGGAATTCAAATGTGCATTCAGAGTTGAGAATCAGATGGATTCTTTCTTTTGTGGAAATGTTTTAT 1681 AATATTGGACTCTTAATCCGCATTTCATTATTAAAGCATGCTGTGGAGAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | TZM-bl |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462573. RNA binding protein: AGO2. Condition:TZM-bl BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | Prostate Tissue | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRX1760639. RNA binding protein: AGO2. Condition:AGO-CLIP-LNCaP-MDV_A
... - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.). |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al. - Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
|
CLIP-seq Support 1 for dataset GSM1462573 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl BaL |
Location of target site | ENST00000383791.3 | 3UTR | AUUGGACUCUUAAUCC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
75 hsa-miR-16-2-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT004488 | RARB | retinoic acid receptor beta | 3 | 1 | ||||||||
MIRT038707 | NUCKS1 | nuclear casein kinase and cyclin dependent kinase substrate 1 | 1 | 1 | ||||||||
MIRT057208 | PPIF | peptidylprolyl isomerase F | 2 | 4 | ||||||||
MIRT058726 | RSBN1 | round spermatid basic protein 1 | 2 | 8 | ||||||||
MIRT074502 | NFATC2IP | nuclear factor of activated T-cells 2 interacting protein | 2 | 4 | ||||||||
MIRT081544 | ZNF431 | zinc finger protein 431 | 2 | 4 | ||||||||
MIRT096893 | ERBB2IP | erbb2 interacting protein | 2 | 2 | ||||||||
MIRT105124 | MYC | MYC proto-oncogene, bHLH transcription factor | 2 | 2 | ||||||||
MIRT107898 | PTAR1 | protein prenyltransferase alpha subunit repeat containing 1 | 2 | 4 | ||||||||
MIRT109432 | KLHL15 | kelch like family member 15 | 2 | 6 | ||||||||
MIRT166742 | PAPD7 | poly(A) RNA polymerase D7, non-canonical | 2 | 6 | ||||||||
MIRT171257 | YWHAG | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma | 2 | 2 | ||||||||
MIRT192760 | B2M | beta-2-microglobulin | 2 | 2 | ||||||||
MIRT194905 | RBBP6 | RB binding protein 6, ubiquitin ligase | 2 | 8 | ||||||||
MIRT215599 | SUB1 | SUB1 homolog, transcriptional regulator | 2 | 2 | ||||||||
MIRT223632 | ATP6V1C1 | ATPase H+ transporting V1 subunit C1 | 2 | 4 | ||||||||
MIRT241605 | AMOTL1 | angiomotin like 1 | 2 | 4 | ||||||||
MIRT291174 | SH3GLB1 | SH3 domain containing GRB2 like, endophilin B1 | 2 | 2 | ||||||||
MIRT444286 | ABCG2 | ATP binding cassette subfamily G member 2 (Junior blood group) | 2 | 2 | ||||||||
MIRT463285 | ZFX | zinc finger protein, X-linked | 2 | 4 | ||||||||
MIRT471759 | NUS1 | NUS1 dehydrodolichyl diphosphate synthase subunit | 2 | 8 | ||||||||
MIRT479611 | CDC25A | cell division cycle 25A | 2 | 2 | ||||||||
MIRT481497 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 | 2 | 8 | ||||||||
MIRT483117 | SH3BP5 | SH3 domain binding protein 5 | 2 | 2 | ||||||||
MIRT502279 | GRPEL2 | GrpE like 2, mitochondrial | 2 | 8 | ||||||||
MIRT507838 | CCNT1 | cyclin T1 | 2 | 2 | ||||||||
MIRT508179 | MTRNR2L6 | MT-RNR2-like 6 | 2 | 4 | ||||||||
MIRT510576 | UBE2D3 | ubiquitin conjugating enzyme E2 D3 | 2 | 6 | ||||||||
MIRT517853 | RPS4X | ribosomal protein S4, X-linked | 2 | 4 | ||||||||
MIRT521690 | PRKAA1 | protein kinase AMP-activated catalytic subunit alpha 1 | 2 | 8 | ||||||||
MIRT525070 | FRK | fyn related Src family tyrosine kinase | 2 | 2 | ||||||||
MIRT527082 | UBE2E3 | ubiquitin conjugating enzyme E2 E3 | 2 | 2 | ||||||||
MIRT529552 | EI24 | EI24, autophagy associated transmembrane protein | 2 | 2 | ||||||||
MIRT530426 | SULT1B1 | sulfotransferase family 1B member 1 | 2 | 2 | ||||||||
MIRT533909 | TBC1D15 | TBC1 domain family member 15 | 2 | 2 | ||||||||
MIRT536627 | IPO7 | importin 7 | 2 | 2 | ||||||||
MIRT537647 | ERGIC2 | ERGIC and golgi 2 | 2 | 4 | ||||||||
MIRT538512 | CLCN3 | chloride voltage-gated channel 3 | 2 | 2 | ||||||||
MIRT539219 | ANP32E | acidic nuclear phosphoprotein 32 family member E | 2 | 6 | ||||||||
MIRT539348 | AGO2 | argonaute 2, RISC catalytic component | 2 | 4 | ||||||||
MIRT539954 | CCT4 | chaperonin containing TCP1 subunit 4 | 2 | 2 | ||||||||
MIRT541208 | HOXA10 | homeobox A10 | 2 | 2 | ||||||||
MIRT543216 | TMEM117 | transmembrane protein 117 | 2 | 2 | ||||||||
MIRT543399 | DROSHA | drosha ribonuclease III | 2 | 2 | ||||||||
MIRT546648 | RPS6KA5 | ribosomal protein S6 kinase A5 | 2 | 2 | ||||||||
MIRT546852 | RAB1A | RAB1A, member RAS oncogene family | 2 | 2 | ||||||||
MIRT549917 | MRPS30 | mitochondrial ribosomal protein S30 | 2 | 2 | ||||||||
MIRT552998 | USP46 | ubiquitin specific peptidase 46 | 2 | 2 | ||||||||
MIRT555254 | PREPL | prolyl endopeptidase-like | 2 | 2 | ||||||||
MIRT555956 | NRIP1 | nuclear receptor interacting protein 1 | 2 | 2 | ||||||||
MIRT557095 | HOXA9 | homeobox A9 | 2 | 2 | ||||||||
MIRT561396 | TUBB2A | tubulin beta 2A class IIa | 2 | 2 | ||||||||
MIRT561654 | RNF219 | ring finger protein 219 | 2 | 2 | ||||||||
MIRT563101 | PABPC4L | poly(A) binding protein cytoplasmic 4 like | 2 | 2 | ||||||||
MIRT565979 | RNF44 | ring finger protein 44 | 2 | 2 | ||||||||
MIRT572396 | CCDC14 | coiled-coil domain containing 14 | 2 | 2 | ||||||||
MIRT574400 | TM9SF3 | transmembrane 9 superfamily member 3 | 2 | 2 | ||||||||
MIRT607623 | VSNL1 | visinin like 1 | 2 | 2 | ||||||||
MIRT610645 | CTGF | connective tissue growth factor | 2 | 2 | ||||||||
MIRT623379 | LPP | LIM domain containing preferred translocation partner in lipoma | 2 | 2 | ||||||||
MIRT624687 | AR | androgen receptor | 2 | 2 | ||||||||
MIRT632089 | ALDH1A2 | aldehyde dehydrogenase 1 family member A2 | 2 | 2 | ||||||||
MIRT644216 | CBS | cystathionine-beta-synthase | 2 | 2 | ||||||||
MIRT647841 | BID | BH3 interacting domain death agonist | 2 | 2 | ||||||||
MIRT651649 | WASF2 | WAS protein family member 2 | 2 | 2 | ||||||||
MIRT689064 | AGMAT | agmatinase | 2 | 2 | ||||||||
MIRT698150 | TNPO1 | transportin 1 | 2 | 2 | ||||||||
MIRT700516 | PTPN14 | protein tyrosine phosphatase, non-receptor type 14 | 2 | 2 | ||||||||
MIRT704081 | DYRK2 | dual specificity tyrosine phosphorylation regulated kinase 2 | 2 | 2 | ||||||||
MIRT705970 | ACBD5 | acyl-CoA binding domain containing 5 | 2 | 2 | ||||||||
MIRT715694 | COMMD3-BMI1 | COMMD3-BMI1 readthrough | 2 | 2 | ||||||||
MIRT717184 | BMI1 | BMI1 proto-oncogene, polycomb ring finger | 2 | 2 | ||||||||
MIRT724607 | AP3B1 | adaptor related protein complex 3 beta 1 subunit | 2 | 2 | ||||||||
MIRT724854 | IGFBP5 | insulin like growth factor binding protein 5 | 2 | 2 | ||||||||
MIRT725401 | LRIG2 | leucine rich repeats and immunoglobulin like domains 2 | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|